ImmunoCellular Therapeutics (OTCBB:IMUC) said Tuesday it has inked a deal with the University of Pennsylvania for an exclusive worldwide license of a patent-pending technology for the production of high-activity dendritic cells.
license covers the application of this technology to the development of
therapeutics for all indications except breast cancer and ductal
carcinoma, the company said.
The terms of the agreement were not disclosed.
licensed technology underlies ICT-107, ImmunoCellular's lead dendritic
cell-based cancer vaccine candidate for the treatment of glioblastoma
multiforme, an aggressive type of brain cancer.
is currently in phase two trials, is a dendritic cell-based vaccine that
works by activating a patient's immune system against specific tumour
associated antigens for glioblastoma multiforme.
This is done by
removing dendritic cells from a patient, loading them with the
tumour-related antigens, and re-injecting them back into the patient's
body to trigger an immune response against cancer cells exhibiting these
Cancer stem cells are thought to be the originators of
common tumour cells, and lead to cancer’s re-growth after chemotherapy.
It is believed that destroying the cancer stem cells will allow for
longer survival, without relapse.
“This licensing agreement
represents an expansion of our intellectual property surrounding the
technology underlying our lead product candidate, ICT-107," said
president and CEO, Manish Singh.
"In addition to contributing to
the powerful immune responses to ICT-107 we have observed to date, this
technology also enables the manufacture of multiple vaccine shots from a
single production run, allowing us to significantly reduce the cost of
manufacturing the vaccine.
"As we continue advancing our ongoing
Phase II trial in glioblastoma, we are confident that will continue to
realize the benefits of the enhanced efficacy and efficiency of this
innovative dendritic-cell production method.”
technology from the University of Pennsylvania, developed by Brian J.
Czerniecki, M.D., allows the development of dendritic cells designed to
trigger powerful and targeted immune responses to specific cancer
In the natural human immune system, dendritic cells
are responsible for capturing, processing and presenting antigens to
T-cells in the immune system, which in turn target the antigens and
These cells' conversion from antigen-capturing to
antigen-presenting mode, known as maturation, relies on the production
of special messenger cells known as cytokines. The licensed technology
produces dendritic cells that express "very high levels of the cytokines
interleukin (IL) -12 and –IP-10", which have been shown to play a key
role in initiating T-cell response, ImmunoCellular said.
is a Los Angeles-based clinical-stage company that is developing
immune-based therapies for the treatment of brain and other cancers.
and overall survival times for GBM patients treated with ICT-107 during
the company's phase one trial of the drug continue to be substantially
longer than those associated with standard of care (SOC) alone,
In September 2011, ImmunoCellular reported
its three-year data, which indicated an overall survival of 55 percent,
compared to 16 percent based on historical SOC.
Of the 16 newly diagnosed patients who received ICT-107, 38 percent continue to sh